A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure - Report - MDSpire
Advertisement
A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure
Clinical Report: Asparaginase Drug Monitoring in High-Risk Pediatric ALL in India
Overview
This pilot study reveals that high-risk pediatric patients with acute lymphoblastic leukemia (ALL) in India exhibit consistently subtherapeutic trough levels of asparaginase during induction therapy. The findings underscore the need for therapeutic drug monitoring to optimize treatment and minimize toxicity.
Background
Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer in India, with survival rates significantly lower than those in high-income countries. Asparaginase is a crucial component of ALL treatment, yet its pharmacokinetics can vary widely among patients. In resource-limited settings, the lack of therapeutic drug monitoring may contribute to inadequate drug exposure and poor clinical outcomes.
Data Highlights
Parameter
Value
Patients Enrolled
30
High-Risk Patients Evaluated
5
Subtherapeutic Trough Activity
All <0.5 IU/mL
Peak Asparaginase Activity Range
0.52–1.97 IU/mL
Median Peak Activity
1.15 IU/mL
Key Findings
All evaluable patients had subtherapeutic trough asparaginase activity (<0.5 IU/mL).
Higher asparaginase activity correlated with treatment-related toxicities, including hepatotoxicity and elevated blood urea nitrogen.
Three out of nine high-risk patients died from treatment-related complications.
The study highlights the potential role of therapeutic drug monitoring in optimizing asparaginase dosing.
Clinical Implications
The findings suggest that routine therapeutic drug monitoring of asparaginase could help ensure adequate drug exposure and minimize toxicities in pediatric ALL patients. Clinicians should consider implementing monitoring protocols, especially in resource-limited settings, to improve treatment outcomes.
Conclusion
This preliminary investigation indicates a critical need for therapeutic drug monitoring in pediatric ALL patients to enhance treatment efficacy and safety. Further studies are warranted to validate these findings and establish appropriate dosing strategies.
